GlassScriptPhysician profile
Timothy M Mcgee
NPI 1720063480
$3,245.36
in general payments reported to CMS, 2019-2025
27 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $243 · 2021: $194 · 2022: $708 · 2023: $524 · 2024: $466 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $656.94 | 2019-2025 | |
| Janssen Biotech, INC. | $326.60 | 2021-2023 | Tremfya, Simponi, Stelara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $199.72 | 2019-2025 | Cabtreo, Duobrii |
| Regeneron Healthcare Solutions, INC. | $174.09 | 2019-2023 | Libtayo |
| Ucb, INC. | $158.56 | 2019-2025 | Bimzelx |
| Amgen INC. | $141.31 | 2019-2025 | Otezla, Otezla |
| Almirall LLC | $139.44 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $138.94 | 2019-2025 | Absorica Ld, Winlevi |
| Leo Pharma INC. | $135.13 | 2022-2024 | Adbry |
| Davol INC. | $127.19 | 2022 | |
| Allergan, INC. | $126.52 | 2019-2022 | |
| Revance Therapeutics, INC. | $119.91 | 2025 | Daxi |
| Incyte Corporation | $109.77 | 2022-2024 | Opzelura |
| Epi Health, LLC | $91.09 | 2019-2021 | |
| Biofrontera INC. | $90.18 | 2019-2023 | Ameluz, Xepi, Bf-Rhodoled |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $73.09 | 2019 | |
| Vyne Pharmaceuticals INC. | $71.11 | 2020-2021 | |
| Galderma Laboratories, L.P. | $63.48 | 2019 | |
| Genzyme Corporation | $62.93 | 2023 | |
| Tela Bio, INC. | $40.06 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Celgene Corporation | $37.86 | 2019 | |
| Lilly USA, LLC | $37.52 | 2021-2024 | Taltz |
| Aclaris Therapeutics, INC. | $36.41 | 2019 | |
| Journey Medical Corporation | $26.80 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $25.78 | 2023 | Sotyktu |
| Covidien LP | $19.49 | 2020 | |
| Dermira, INC. | $15.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Mcgee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.